Cargando…

Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study

BACKGROUND: Change in forced expiratory volume in one second (FEV(1)) is important for defining severity of chronic obstructive pulmonary disease (COPD). Serological neoepitope markers of collagen turnover may predict rate of change in FEV(1). METHODS: One thousand COPD subjects from the observation...

Descripción completa

Detalles Bibliográficos
Autores principales: Leeming, Diana J., Byrjalsen, Inger, Sand, Jannie M. B., Bihlet, Asger R., Lange, Peter, Thal-Singer, Ruth, Miller, Bruce E., Karsdal, Morten A., Vestbo, Jørgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716018/
https://www.ncbi.nlm.nih.gov/pubmed/29202744
http://dx.doi.org/10.1186/s12890-017-0505-4
_version_ 1783283860646133760
author Leeming, Diana J.
Byrjalsen, Inger
Sand, Jannie M. B.
Bihlet, Asger R.
Lange, Peter
Thal-Singer, Ruth
Miller, Bruce E.
Karsdal, Morten A.
Vestbo, Jørgen
author_facet Leeming, Diana J.
Byrjalsen, Inger
Sand, Jannie M. B.
Bihlet, Asger R.
Lange, Peter
Thal-Singer, Ruth
Miller, Bruce E.
Karsdal, Morten A.
Vestbo, Jørgen
author_sort Leeming, Diana J.
collection PubMed
description BACKGROUND: Change in forced expiratory volume in one second (FEV(1)) is important for defining severity of chronic obstructive pulmonary disease (COPD). Serological neoepitope markers of collagen turnover may predict rate of change in FEV(1). METHODS: One thousand COPD subjects from the observational, multicentre, three-year ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study (NCT00292552, trial registration in February 2006) were included. Matrix metalloproteinase (MMP)-generated fragments of collagen type I, and type VI (C1M and C6M) were assessed in month six serum samples. A random-coefficient model with both a random intercept and a random slope was used to test the ability of the markers to predict post-dose bronchodilator FEV(1) (PD-FEV(1)) change over two years adjusting for sex, age, BMI, smoking, bronchodilator reversibility, prior exacerbations, emphysema and chronic bronchitis status at baseline. RESULTS: Annual change of PD-FEV(1) was estimated from a linear model for the two-year study period. Serum C1M and C6M were independent predictors of lung function change (p = 0.007/0.005). Smoking, bronchodilator reversibility, plasma hsCRP and emphysema were also significant predictors. The effect estimate between annual change in PD-FEV(1) per one standard deviation (1SD) increase of C1M and C6M was +10.4 mL/yr. and +8.6 mL/yr. C1M, and C6M, had a significant association with baseline FEV(1). CONCLUSION: We demonstrated that markers of tissue turnover were significantly associated with lung function change. These markers may function as prognostic biomarkers and possibly as efficacy biomarkers in clinical trials focusing on lung function change in COPD. TRIAL REGISTRATION: NCT00292552, Retrospectively registered, trial registration in February 2006. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-017-0505-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5716018
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57160182017-12-08 Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study Leeming, Diana J. Byrjalsen, Inger Sand, Jannie M. B. Bihlet, Asger R. Lange, Peter Thal-Singer, Ruth Miller, Bruce E. Karsdal, Morten A. Vestbo, Jørgen BMC Pulm Med Research Article BACKGROUND: Change in forced expiratory volume in one second (FEV(1)) is important for defining severity of chronic obstructive pulmonary disease (COPD). Serological neoepitope markers of collagen turnover may predict rate of change in FEV(1). METHODS: One thousand COPD subjects from the observational, multicentre, three-year ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study (NCT00292552, trial registration in February 2006) were included. Matrix metalloproteinase (MMP)-generated fragments of collagen type I, and type VI (C1M and C6M) were assessed in month six serum samples. A random-coefficient model with both a random intercept and a random slope was used to test the ability of the markers to predict post-dose bronchodilator FEV(1) (PD-FEV(1)) change over two years adjusting for sex, age, BMI, smoking, bronchodilator reversibility, prior exacerbations, emphysema and chronic bronchitis status at baseline. RESULTS: Annual change of PD-FEV(1) was estimated from a linear model for the two-year study period. Serum C1M and C6M were independent predictors of lung function change (p = 0.007/0.005). Smoking, bronchodilator reversibility, plasma hsCRP and emphysema were also significant predictors. The effect estimate between annual change in PD-FEV(1) per one standard deviation (1SD) increase of C1M and C6M was +10.4 mL/yr. and +8.6 mL/yr. C1M, and C6M, had a significant association with baseline FEV(1). CONCLUSION: We demonstrated that markers of tissue turnover were significantly associated with lung function change. These markers may function as prognostic biomarkers and possibly as efficacy biomarkers in clinical trials focusing on lung function change in COPD. TRIAL REGISTRATION: NCT00292552, Retrospectively registered, trial registration in February 2006. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-017-0505-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-04 /pmc/articles/PMC5716018/ /pubmed/29202744 http://dx.doi.org/10.1186/s12890-017-0505-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Leeming, Diana J.
Byrjalsen, Inger
Sand, Jannie M. B.
Bihlet, Asger R.
Lange, Peter
Thal-Singer, Ruth
Miller, Bruce E.
Karsdal, Morten A.
Vestbo, Jørgen
Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study
title Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study
title_full Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study
title_fullStr Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study
title_full_unstemmed Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study
title_short Biomarkers of collagen turnover are related to annual change in FEV(1) in patients with chronic obstructive pulmonary disease within the ECLIPSE study
title_sort biomarkers of collagen turnover are related to annual change in fev(1) in patients with chronic obstructive pulmonary disease within the eclipse study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716018/
https://www.ncbi.nlm.nih.gov/pubmed/29202744
http://dx.doi.org/10.1186/s12890-017-0505-4
work_keys_str_mv AT leemingdianaj biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT byrjalseninger biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT sandjanniemb biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT bihletasgerr biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT langepeter biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT thalsingerruth biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT millerbrucee biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT karsdalmortena biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy
AT vestbojørgen biomarkersofcollagenturnoverarerelatedtoannualchangeinfev1inpatientswithchronicobstructivepulmonarydiseasewithintheeclipsestudy